Incyte’s first quarter results were shaped by strong demand across its commercial portfolio, with growth supported by both new and existing products in hematology, oncology, and immunology. Management cited successful execution in advancing late-stage pipeline programs, as well as increased prescription volume in key brands like Jakafi and Opzelura. CEO William Meury pointed to the company’s strategic transition beyond its cornerstone product, emphasizing, “We view '26 as a year of strategic progress as we transition Incyte beyond a single cornerstone product toward a high-quality, growth-oriented portfolio across hematology, oncology and immunology.”

Is now the time to buy INCY? Find out in our full research report (it’s free for active Edge members).

While we enjoy listening to the management's commentary, our favorite part of earnings calls are the analyst questions. Those are unscripted and can often highlight topics that management teams would rather avoid or topics where the answer is complicated. Here is what has caught our attention.

Our Top 5 Analyst Questions From Incyte’s Q1 Earnings Call

• Tazeen Ahmad (Bank of America): asked about the commercial overlap between Opzelura and povorcitinib for vitiligo. CEO William Meury and Mohamed Issa explained the benefit of offering both topical and oral solutions, targeting different patient segments and enabling broader market coverage.
• James Shin (Deutsche Bank): inquired about the substance of upcoming 989 data at EHA and changes under new CFO Suky Upadhyay. Cagnoni emphasized the evolving data set and continued evidence of disease modification, while Meury highlighted Upadhyay’s focus on efficient capital allocation and scalable processes.
• Stephen Willey (Stifel): questioned the dose escalation mechanics in the 989 ET trial and potential regulatory flexibility for MF. Cagnoni described early dose escalation for non-responders and anticipated constructive FDA discussions about endpoints for MF studies.
• Etzer Darout (Barclays): sought clarification on timeline updates for Niktimvo and Jakafi combination studies in GVHD. Management noted quicker-than-expected patient accrual, leading to earlier data and potential acceleration of regulatory strategy.
• Judah Frommer (Morgan Stanley): asked about market dynamics for nonsteroidal topicals and the importance of having both Opzelura and povorcitinib for future growth. Meury emphasized that having both products allows Incyte to serve a wide range of patient needs and positions the company well in a growing market.

Catalysts in Upcoming Quarters

In the coming quarters, our team will monitor (1) regulatory decisions and launch execution for Jakafi XR, Opzelura in Europe, Monjuvi in first-line DLBCL, and povorcitinib in HS; (2) key late-stage clinical trial readouts in hematology and oncology, particularly for the mutant CALR antibody and KRAS G12D inhibitor; and (3) the impact of recent leadership changes and commercial integration efforts on launch effectiveness. Success in these areas could determine whether Incyte achieves its near- and long-term growth ambitions.

Incyte currently trades at $97.15, up from $95.72 just before the earnings. At this price, is it a buy or sell? Find out in our full research report (it’s free).

Our Favorite Stocks Right Now

ONE MORE THING: Top 6 Stocks for This Week. This market is separating quality stocks from expensive ones fast. AI taking down whole sectors with no warning. In a rotation this fast, you need more than a list of good companies.

Our AI system flagged Palantir before it ran 1,662%. AppLovin before it ran 753%. Nvidia before it ran 1,178%. Each week it produces 6 new names that pass the same tests. Get Our Top 6 Stocks for Free HERE.

Stocks that have made our list include now familiar names such as Nvidia (+1,326% between June 2020 and June 2025) as well as under-the-radar businesses like the once-micro-cap company Tecnoglass (+1,754% five-year return). Find your next big winner with StockStory today.